Abetalipoproteinemia Management Market

Abetalipoproteinemia Management Market Snapshot (2023 to 2033)

The Global Abetalipoproteinemia Management Market is expected to surpass an impressive valuation of USD 147 million in 2023 and is projected to reach USD 341 million by 2033, growing at a CAGR of 8.78 %.

Rising prevalence of imaging studies like hepatic scans or ultrasonography to assess changes in fatty liver, Magnetic resonance imaging (MRI) of the spinocerebellar region which may show degeneration will drive the market of Abetalipoproteinemia during the forecast period.

Increasing incidences of inborn metabolic disorders due to changing lifestyles of a child’s parents are likely to propel market growth. However, the high cost of treatment and dearth of awareness will restrain market expansion.

Data Points	Key Statistics
Expected Market Value (2023)	USD 147 million
Anticipated Forecast Value (2033)	USD 341 million
Projected Growth Rate (2023 to 2033)	CAGR 8.78 %

2018 to 2022 Abetalipoproteinemia Management Demand Analysis vs. Forecast 2023 to 2033

The market of Abetalipoproteinemia grossed a valuation of USD 110 million in 2018 while growing at a CAGR of 5.97 %. The growth is attributable to various factors including high-dose vitamin supplementation, which is the mainstay for treatment and may prevent, delay, or alleviate the complications and improve the prognosis, enabling some patients to live to the eighth decade of life.

The diagnostic criteria and entry criterion of low-density lipoprotein cholesterol (LDL-C) 15 mg/dL and apoB 15 mg/dL can be useful in universal or opportunistic screening for Abetalipoproteinemia. Registry research on Abetalipoproteinemia is currently ongoing to better understand the disease burden and unmet needs of this life-threatening disease with few therapeutic options.

Other mainstays of treatment include adherence to a low-fat diet and supplementation with essential fatty acids. Prognosis is variable, but early diagnosis and strict adherence to treatment can recover normal neurological function and halt disease progression which will lead to market expansion in the forecast period. Considering these factors and developments, FMI has estimated the market of Abetalipoproteinemia to garner a valuation of USD 341 million with a CAGR of 8.78 % by end of the forecast period.

Which are Some Prominent Drivers of the Abetalipoproteinemia management market?

Technological Advancements fuelling the Market Expansion

Growth in the well-structured diagnostic treatment facility will uplift the market growth, also a rise in the research and development activities in the market, Rise in the healthcare expenditures, and increasing demand from emerging economies are some of the crucial factors among others propelling abetalipoproteinemia treatment market growth.

Moreover, the rise in technological advancements and modernization in healthcare machinery and growth in demand from emerging economies will further open up new avenues for the abetalipoproteinemia treatment market in the forecast period of 2023 to 2033. Along with this, the growing demand for one-time therapies against inborn metabolic disorders is likely to serve as a revenue generator in the Abetalipoproteinemia diagnostics market.

What are the Challenges Projected to be Faced by the Market?

High Cost of Diagnostic Tests likely to stymie Uptake

There have been several tests that are immensely available for testing inborn metabolic disorders like Abetalipoproteinemia. But these tests are of a growing cost that is not affordable for several patients, mostly belonging to the lower economic groups. Therefore, it restrains market growth.

Region-Wise Insights

What is The Growth Outlook in North America?

North America dominating the Market with Highest Market Share

This region is expected to dominate the market with a 39% market share while exhibiting a CAGR of 7.5% by end of the forecast period. A superior healthcare system and advancement in research & development in the field are propelling market growth in the region.

Moreover, high healthcare expenditure and rising awareness about inborn metabolic disorders are anticipated to drive the regional market further.

What are the growth prospects in South Asia?

South Asia to reflect the fastest growth in the Forecast Period

The abetalipoproteinemia management market in this region will witness the fastest CAGR of 8% during the forecast period. The market is projected to be worth around USD 110 million by end of the forecast period. China will lead the market with an estimated valuation of USD 65 million, growing at a CAGR of 8.9% during the forecast period.

The growth is attributable to rapid economic development, rising demand for molecular genetic testing, and hypercholesterolemia diseases, along with increased disposable income levels are propelling growth in this region. Moreover, rising cases of malnutrition in these regions will also aid in market expansion.

Category wise Insights

By Treatment Type, which segment is most likely to dominate the market?

Blood Testing Treatment to possess Highest Market Share

The blood testing treatment market is expected to dominate the market with a segment share of 61.7% by end of the forecast period. Rising adoption of blood tests to detect low levels of both lipids, such as cholesterol and triglycerides, and lipid-soluble vitamins such as A, E, and K to diagnose Abetalipoproteinemia will augment this segment’s growth.

By End User, which Segment will possess a Significant Market Share?

Hospitals and clinics dominate the market with substantial market revenue

Hospitals & clinics are projected to lead the market with a contribution of around 71% during the forecast period. Increasing investment by industry players in Research and development activities is augmenting the segment’s growth. Furthermore, the rapid adoption of new novel therapies and drugs in hospitals is also leading to market expansion.

Start-ups in Abetalipoproteinemia Management Market

Founded in 2022, Alnylam is a US-based company that develops RNA interference-based therapeutics for disorders like Abetalipoproteinemia. The company's pipeline includes drugs that are used to treat hereditary ATTR Amyloidosis, acute hepatic porphyria, and treating hypercholesterolemia.

Also, it develops drugs for cardiometabolic diseases, infectious diseases, central nervous system, and ocular diseases. I received funding of USD 17 million from Blackstone, Genzyme, Polaris Partners, and 11 Other Investors.

Founded in 2015, ‘Fulcrum Therapeutics’ is a US-based startup that focuses on discovering and developing small molecules that modulate the on/off control mechanisms that regulate genes. The Fulcrum product engine integrates insights from four scientific disciplines (Gene Regulation, Human Genetics and Disease, Cell Biology, and Screening and Computation) to identify novel drug targets and develop breakthrough medicines.

The early focus of Fulcrum’s product engine is on two severe genetic diseases: Fragile X syndrome (FXS) and a form of muscular dystrophy called facioscapulohumeral muscular dystrophy (FSHD).

Each disease arises from a single gene mutation that creates an error in gene regulation. In the case of Fragile X, the silencing of the FMR1 gene eliminates the cell’s ability to make a protein needed for brain function. In FSHD, the precipitating event is the activation of a gene called DUX4 that should be silent in adulthood.

This activation leads to muscle wasting as cells die. It received funding of USD 115 million from EcoR1, Highliner Capital, Boxer Capital, and 14 Other Investors.

Market Competition

The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost the market growth. The major players in the market are Lonza, Piramal Pharma Solutions, Abbott Laboratories, Koninklijke DSM N.V., Barrington Nutritionals, Ion Labs Inc, Galderma Laboratories, Johnson & Johnson Services, Inc, Medimetriks Pharmaceuticals, Inc., and F-Hoffmann-La Roche.

Some Recent Developments in this industry are:

• In 2021, Eli Lilly and Company announced the acquisition of Protomer Technologies. Protomer's proprietary peptide- and protein-engineering platform is used to detect and synthesize molecules that can sense glucose and other endogenous modulators of protein activity.
• In 2020, Lumen announced the discovery of a metabolism-tracking wellness device that offers real-time data with a person’s breath and also helps in maintaining fitness, weight loss, and others.
• On February 17, 2022, Maze Therapeutics, a company translating genetic insights into new precision medicines, announced the initiation of dosing in the company’s Phase 1 clinical trial of MZE001 in healthy volunteers. MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup, is being evaluated for the potential oral treatment of patients with late-onset Pompe Disease
• In March 2022, Lumen released a platform that allows users to log and track the nutritional value and macronutrients of every item (volumes of fats, carbohydrates, and protein) and meal in order to measure the direct influence of their dietary choices on their metabolism.
• In April 2022, Bengaluru-based HealthifyMe launched HealthifyPro combining some of the most advanced technologies in the field of metabolic health to drive behavior change.

Report Scope

Report Attribute	Details
Market Value in 2023	USD 147 million
Market Value in 2033	USD 341 million
Growth Rate	CAGR of 8.78% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Treatment, End User, Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa (MEA)
Key Countries Profiled	USA, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, India, China, Japan, India, Malaysia, Singapore, Thailand, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel
Key Companies Profiled	Lonza Group; Piramal Pharma Solutions; Abbott Laboratories; Koninklijke DSM N.V; Barrington Nutritionals; Ion Labs Inc.; Galderma Laboratories; Johnson & Johnson Services Inc.; Medimetriks Pharmaceuticals Inc.; F to Hoffmann to La Roche Ltd.
Customization	Available Upon Request

Key Segments Profiled in the Abetalipoproteinemia management Industry Survey

By Treatment:

• Molecular Genetic Testing Treatment
• Blood Testing Treatment
• Fat-Soluble Vitamins Supplementation
• Others

By End User:

• Hospitals & Clinics
• Diagnostics labs
• Others

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Frequently Asked Questions

Which Country is Set to Register Exponential Growth in the Market?

Japan may witness significant growth in the abetalipoproteinemia management market.

What Drives Sales of Abetalipoproteinemia Management Market?

New product launches and government initiatives drive sales of abetalipoproteinemia management.

What Key Trends are Shaping the Abetalipoproteinemia Management Market?

Technological advancements and rising prevalence of the disease.

How was the Historical Performance of the Abetalipoproteinemia Management Market?

The market grossed a valuation of USD 110 million in 2018 while growing at a CAGR of 5.97 %.

What Opportunities Await for the Market Players?

Substantial investment in research and development, marketing and sales.